RNA splicing is the cellular process that has only recently been found to be an important target for various cancers. Among the spliceosome genes that are involved in cancers, SF3B1 is most frequently mutated. Recurrent mutation in codon 625 has been found in uveal melanoma, but this mutation has not been identified in cutaneous melanoma. We used whole-exome sequencing to explore the mutational landscape of 295 melanoma samples, 231 of which are cutaneous melanoma. Among these cutaneous melanoma samples, we found two samples with R625 mutation in SF3B1 gene. The results were validated by Sanger sequencing. We conclude that SF3B1 R625 mutation does occur in cutaneous melanoma, although with a low frequency (B1%).
Introduction
Recent high-throughput sequencing of cancer genomes has led to new discoveries of mutations in cellular processes that were not previously known to have a causal role in cancer. One such process is RNA splicing (for a review see [1] ). Among the recently discovered spliceosome genes that are involved in cancers, SF3B1 is the most frequently mutated. SF3B1 mutations are found with high frequency in myelodysplastic syndromes (MDS) and chronic myelogenous leukemia (CLL); it is also mutated in solid tumors such as lung adenocarcinomas, breast cancer, and pancreatic cancer. In uveal melanoma, recurrent mutations at codon 625 of SF3B1 have been identified [2] [3] [4] .
SF3B1 encodes subunit one of the splicing factor 3b protein complex, which is part of the U2 small nuclear RNAs (snRNP) that binds pre-mRNA upstream of the intron's branch site. SF3B1 mutations usually occur within the 22 HEAT repeats in the C-terminal region. Codon R625 has the highest mutation frequency in uveal melanoma [2] [3] [4] , whereas the mutation hotspot is at K700 for MDS and CLL.
Although multiple groups identified SF3B1 R625 mutations in uveal melanoma [2] [3] [4] , none of them identified this mutation in cutaneous melanoma [5] . We have sequenced the whole exome of a cohort of 295 melanoma samples, 231 of which are cutaneous melanoma [6] . We report here that, although the frequency is low, SF3B1 R625 mutation does occur in cutaneous melanoma.
Materials and methods

Sample selection
For details of sample selection, see Krauthammer et al. [6] .
Exome sequencing and data analysis
For details of exome sequencing and data analysis, see reference Krauthammer et al. [6] .
Sanger sequencing
The following primers were used to amplify the region of the SF3B1 R625 for validation by Sanger sequencing: F1: 5 0 -CCTCGTGGTCATTGAACCGC-3 0 ; B1: 5 0 -ACTT CTAAGATGTGGCAAGATGGC-3 0 .
Results
Our cohort contains all samples described previously [6] along with additional samples ( Table 1 ). The whole-exome sequencing of 295 melanoma samples identified five with mutations in SF3B1 R625 ( Table 2 ). Of these five samples, two (YUBOO and G2306T) are uveal melanoma, two (YUPAO and YUGAFFE) are cutaneous melanoma, and one sample for which the location of the primary lesion is unknown (YUKAY). Three samples have p.R625H mutation, whereas the other two have p.R625C mutation (amino acids are numbered based on GenBank accession NM_012433.2). The alignments of reads from whole-exome sequencing around the mutations convincingly show that the mutations are authentic, even though the mutation frequency is low. The whole-exome sequencing results were validated by Sanger sequencing, as shown in Fig. 1 . The mutation peaks in both samples are weak when compared with the reference peaks. These mutation peaks, however, correlate with the mutation frequencies detected in the whole-exome sequencing. For the cutaneous sample YUPAO (shown in the top of Fig. 1 ), there are a total of 251 reads mapped to this position, with the number of reads for each base as: A = 0, C = 211 (84%, 80 + , 131 -), G = 0, T = 40 (16%, 15 + , 25 -). The ' + ' and ' -' signs indicate the numbers of reads in the forward and reverse strands, respectively. SF3B1 is on the reverse strand of hg19 reference genome and the bases shown here are the original counts on hg19 forward strand. For the uveal sample YUBOO (shown in the bottom of Fig. 1 ), there are a total of 137 reads, with the number of reads for each base as: A = 0, C = 112 (82%, 39 + , 73-), G=0, T=25 (18%, 9+, 16-). The other samples with mutations in SF3B1 R625 show similar mutation frequencies. The low mutation frequencies might reflect the presence of stroma in the samples. The matching normal DNAs available for four of the five samples were all wild type, indicating the somatic origin SF3B1 R625.
One melanoma sample in this cohort has the BRAF V600 mutation (YUGAFFE) and none has the NRAS mutation ( Table 2) .
Other SF3B1 nonsynonymous somatic mutations were also present as listed in Table 3 (amino acids are numbered based on GenBank accession NM_012433.2). 
Discussion
The report of mutations in codon 625 of SF3B1 in uveal melanoma [2] [3] [4] prompted further investigation regarding the presence of this mutation in cutaneous melanoma [5] . The published study examined 85 cutaneous melanoma samples using direct Sanger sequencing [5] . The cohort included 22 superficial spreading, 24 acral lentiginous, 36 nodular, and three lentigo maligna melanomas. The mutation was not detected in 81 samples (four samples failed or were ambiguous in the sequencing). In our larger cohort, we found five samples with SF3B1 R625 mutations, two of which are cutaneous melanoma and one of unknown origin, showing that the mutation does occur in this type of melanoma, although at low frequency.
We also noticed that most of our samples that have SF3B1 R625 mutations are metastatic melanoma. This is in contrast to previous finding that SF3B1 R625 mutations are rare in metastatic tumors and are associated with better prognosis [2, 4, 7] . Harbour et al. [2] did not detect any SF3B1 mutation in their five distant metastatic uveal melanoma, and Griewank et al. [7] found one of 26 metastatic uveal melanoma samples. The difference might be due to sample bias, since there are more metastatic than primary tumors in our cohort. The other possibility is that the SF3B1 mutations might play different roles in uveal and cutaneous melanomas. SF3B1 mutations have been found to be associated with different prognosis in different type of cancers. The SF3B1 mutations in CLL are associated with a poorer prognosis [8] , whereas in MDS the mutations are associated with a better prognosis [9] .
Different cancers also have different predominate mutations in SF3B1. In hematological, breast, and pancreatic cancers, codon K700 mutations predominate, whereas in uveal melanoma the R625 codon mutations predominate. We did not detect any K700 mutation in our cohort. It seems that SF3B1 plays different roles in the biology of different cancers. Although now it is clear that SF3B1, as well as other proteins involved in RNA splicing, play a causal role in cancer, the exact effect of the mutations on protein functions and splicing patterns still needs to be fully elucidated by further experiments.
We identitifed five mutations in BAP1 in uveal (three splice site mutations and two InDels), and 10 in cutaneous melanomas (nine SNVs and one InDel). Another gene, EIF1AX, which encodes eukaryotic translation initiation factor 1A (eIF1A), was also recently found to be frequently mutated in uveal melanoma [3] . Interestingly, in our cohort we also found EIF1AX mutations in both uveal and cutaneous melanomas. We found six mutations in 25 uveal melanomas (B24%) and five mutations in 231 cutaneous melanomas (B2%). As discovered previously in uveal melanomas [3] , the nonsynonymous EIF1AX mutations are clustered around the N terminus of the protein for both cutaneous and uveal melanomas in our cohort (data not shown). It would be interesting to see if interactions between the different cellular machinery encoded by these two genes play a role in uveal and cutaneous melanoma biology.
